Maxim Group Begins Coverage on OS Therapies (NYSE:OSTX)

Maxim Group started coverage on shares of OS Therapies (NYSE:OSTX) in a research report released on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $8.00 price target on the stock.

OSTX has been the subject of several other reports. EF Hutton Acquisition Co. I upgraded shares of OS Therapies to a “strong-buy” rating in a report on Tuesday, September 3rd. Brookline Capital Management raised shares of OS Therapies to a “strong-buy” rating in a research report on Thursday, August 22nd.

OS Therapies Stock Up 3.9 %

Shares of OSTX opened at $2.14 on Tuesday. OS Therapies has a one year low of $1.58 and a one year high of $4.90. The stock has a 50-day moving average price of $2.72.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new stake in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.